Intellipharmaceutics International Inc. (IPCI)

[BioSpecialist]

Back in this Goldmine

FIRST FDA APPROVAL EXPECTED IN THIS 3Q 2013....

This LOW FLOAT Monster awaiting 8 FDA approvals.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including two Potential Blockbuster .CEO is the largest Shareholder with over 6 Million Shares .

FOCALIN alone which is Partnered with Par Pharma will drive this Sleeping Giant into Profitability quickly after Market Launch because of the low Burn-rate of around $7 M a year !

4-6 FDA APPROVALS COMING WITHIN NEXT 12 MONTHS = NEXT BILLION DOLLAR COMPANY HERE !

Patience here will payoff big time ! GLTA

Intellipharmaceutics (IPCI)

Market Cap:$ 38 M
Price: $1.90

Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M

8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.

Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercia/launch of the product by Par .